Ultrasound and Near Infrared Imaging for Predicting and Monitoring Neoadjuvant Treatment

Not Applicable

Completed

• Conditions: Breast Cancer; Breast Tumors; Cancer of the Breast; Malignant Neoplasm of Breast; Cancer of Breast

• Registration Number: NCT02891681
• Lead Sponsor: Washington University School of Medicine

Brief Summary

To determine the accuracy of NIR/US assessment of tumor vasculature and oxygen changes in predicting and monitoring early neoadjuvant treatment response compared to pathological response.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2016-08-31
• Study First Submitted QC: 2016-08-31
• Study First Posted: 2016-09-07
• Study Start: 2016-11-29
• Primary Completion: 2020-01-23
• Study Completion: 2020-01-23
• Status Verified: 2021-01
• Results First Submitted: 2021-01-06
• Results First Submitted QC: 2021-01-28
• Last Update Submitted: 2021-01-28
• Results First Posted: 2021-02-16
• Last Update Posted: 2021-02-16

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Female
• Target Recruitment: 41

Inclusion Criteria

• Scheduled to receive neoadjuvant chemotherapy for the treatment of newly diagnosed, locally advanced breast cancer or scheduled to receive neoadjuvant endocrine therapy with the eventual goal of surgery of newly diagnosed clinical stage II-III ER+ HER2- breast cancer (for the endocrine therapy cohort)
• At least 18 years of age
• Female
• Able to understand and willing to sign an IRB-approved written informed consent document

Exclusion Criteria

• Pregnant and/or breastfeeding
• Prior history of breast cancer
• Prior history of chest wall radiation
• Prior history of breast reconstruction, reduction, or augmentation

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
Pathologic Response Based on Miller-Payne Grading System	Up to 6 months	In the Miller-Payne system, the pathologic response is divided into 5 grades based on comparison of tumor cellularity between pre-neoadjuvant core biopsy and definitive surgical specimen as: * grade 1: no change or some alteration to individual malignant cells but no reduction in overall cellularity (pNR); * grade 2: a minor loss of tumor cells but overall cellularity still high; up to 30% (pPR); * grade 3: between an estimated 30% and 90% reduction in tumor cells (pPR); * grade 4: a marked disappearance of tumor cells such that only small clusters or widely dispersed individual cells remain (almost pCR); more than 90% loss of tumor cells; * grade 5: no malignant cells identifiable in sections from the site of the tumor; only vascular fibroelastonic stroma remains often containing macrophages (pCR) (however, ductal carcinoma in situ (DCIS) may be present)

Trial Locations

Locations (1)

Washington University School of Medicine; 🇺🇸 Saint Louis, Missouri, United States